Opening book details…
Can I read Correction to: A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1) on EtoBox?
Correction to: A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1) by Hideki Nakayama; Chitose Ogawa; Masahiro Sekimizu; Hiroyuki Fujisaki; Yoshiyuki Kosaka; Hiroya Hashimoto; Akiko M. Saito; Keizo Horibe is a Medicine article available to read on EtoBox.
What is Correction to: A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1) about?
In the original publication of the article, in "Results" section under the heading "Efficacy" in page number 617, the fourth sentence should be "The median time to CR or CRi was 21 days (range: 18-44 days)." Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Who reads Correction to: A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1)?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Hideki Nakayama; Chitose Ogawa; Masahiro Sekimizu; Hiroyuki Fujisaki; Yoshiyuki Kosaka; Hiroya Hashimoto; Akiko M. Saito; Keizo Horibe
- Publisher
- Springer Science and Business Media LLC
- Published
- 2023
- Language
- EN
- Field
- Medicine (Health Sciences)